岩本高行

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development

フルテキストURL	fulltext.pdf
著者	Fujihara, Miwa\| Shien, Tadahiko\| Shien, Kazuhiko\| Suzawa, Ken\| Takeda, Tatsuaki\| Zhu, Yidan\| Mamori, Tomoka\| Otani, Yusuke\| Yoshioka, Ryo\| Uno, Maya\| Suzuki, Yoko\| Abe, Yuko\| Hatono, Minami\| Tsukioki, Takahiro\| Takahashi, Yuko\| Kochi, Mariko\| Iwamoto, Takayuki\| Taira, Naruto\| Doihara, Hiroyoshi\| Toyooka, Shinichi\|
キーワード	breast cancer YES1 T-DM1 dasatinib drug resistance
発行日	2021-11-26
出版物タイトル	International Journal Of Molecular Sciences
巻	22巻
号	23号
出版者	MDPI
開始ページ	12809
ISSN	1422-0067
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
著作権者	© 2021 by the authors.
論文のバージョン	publisher
PubMed ID	34884609
DOI	10.3390/ijms222312809
Web of Science KeyUT	000735641400001
関連URL	isVersionOf https://doi.org/10.3390/ijms222312809

The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs

フルテキストURL	fulltext.pdf
著者	Iwamoto, Takayuki\| Fujisawa, Tomomi\| Shien, Tadahiko\| Araki, Kazuhiro\| Sakamaki, Kentaro\| Sangai, Takafumi\| Kikawa, Yuichiro\| Takao, Shintaro\| Nishimura, Reiki\| Takahashi, Masato\| Aihara, Tomohiko\| Mukai, Hirofumi\| aira, Naruto\|
キーワード	Metastatic breast cancer Endocrine therapies Estrogen receptor-positive HER2-negative Resistance
発行日	2020-05-11
出版物タイトル	Breast Cancer
巻	27巻
号	5号
出版者	Springer
開始ページ	973
終了ページ	981
ISSN	13406868
NCID	AA1103354X
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
論文のバージョン	author
PubMed ID	32394413
DOI	10.1007/s12282-020-01095-y
Web of Science KeyUT	000531780600002
関連URL	isVersionOf https://doi.org/10.1007/s12282-020-01095-y

Simultaneous hot and cold thyroid nodules: Which is malignant?

フルテキストURL	fulltext.pdf
著者	Otsuka, Yuki\| Nakano, Yasuhiro\| Omura, Daisuke\| Iwamoto, Takayuki\| Hayashi, Ruiko\| Otsuka, Fumio\|
キーワード	autonomous functioning thyroid nodule hyperthyroidism thyroid papillary cancer toxic multinodular goiter
発行日	2021-01-26
出版物タイトル	Clinical Case Reports
巻	9巻
号	3号
出版者	Wiley
開始ページ	1810
終了ページ	1811
ISSN	2050-0904
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
著作権者	© 2021 The Authors.
論文のバージョン	publisher
DOI	10.1002/ccr3.3843
Web of Science KeyUT	000611662800001
関連URL	isVersionOf https://doi.org/10.1002/ccr3.3843

Recurring radiation-induced angiosarcoma of the breast that was treated with paclitaxel chemotherapy: a case report

フルテキストURL	fulltext.pdf
著者	Suzuki, Yoko\| Taniguchi, Kohei\| Hatono, Minami\| Kajiwara, Yukiko\| Abe, Yuko\| Kawada, Kengo\| Tsukioki, Takahiro\| Kochi, Mariko\| Nishiyama, Keiko\| Iwamoto, Takayuki\| Ikeda, Hirokuni\| Shien, Tadahiko\| Taira, Naruto\| Tabata, Masahiro\| Yanai, Hiroyuki\| Doihara, Hiroyoshi\|
キーワード	Radiation-induced angiosarcoma Radiotherapy Breast-conserving surgery Breast cancer Paclitaxel therapy Adjuvant therapy of angiosarcoma
発行日	2020-01-16
出版物タイトル	Surgical Case Reports
巻	6巻
号	1号
出版者	SpringerOpen
開始ページ	25
ISSN	2198-7793
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
著作権者	© The Author(s). 2020
論文のバージョン	publisher
PubMed ID	31950295
DOI	10.1186/s40792-020-0790-7
Web of Science KeyUT	000513920900001
関連URL	isVersionOf https://doi.org/10.1186/s40792-020-0790-7

Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer:NACED-Randomized Multicenter Phase II Trial

JaLCDOI	10.18926/AMO/53675
フルテキストURL	69_5_291.pdf
著者	Sugiu, Kumi\| Iwamoto, Takayuki\| Kelly, Catherine M.\| Watanabe, Naoki\| Motoki, Takayuki\| Itoh, Mitsuya\| Ohtani, Shoichiro\| Higaki, Kenji\| Imada, Takako\| Yuasa, Takeshi\| Omori, Masako\| Sonobe, Hiroshi\| Fujiwara, Toshiyoshi\| Matsuoka, Junji\|
抄録	Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
キーワード	breast cancer neoadjuvant chemotherapy concurrent hormone therapy estrogen receptor positive tumor response
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2015-10
巻	69巻
号	5号
出版者	Okayama University Medical School
開始ページ	291
終了ページ	299
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	26490026
Web of Science KeyUT	000365519600005

NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy

著者	Iwamoto, Takayuki\| Hara, Fumikata\| Uemura, Yukari\| Mukai, Hirofumi\| Watanabe, Toru\| Ohashi, Yasuo\|
キーワード	Chemotherapy-induced amenorrhea Taxane Taxane Breast cancer Guarantee-time bias Premenopause
発行日	2020-05-28
出版物タイトル	Breast Cancer Research and Treatment
巻	182巻
号	2号
出版者	Springer
開始ページ	325
終了ページ	332
ISSN	0167-6806
NCID	AA10623184
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
論文のバージョン	author
PubMed ID	32462261
DOI	10.1007/s10549-020-05692-5
Web of Science KeyUT	000539434600002
関連URL	isVersionOf https://doi.org/10.1007/s10549-020-05692-5

Influences of preoperative metformin on immunological factors in early breast cancer

フルテキストURL	CCP_fulltext.pdf
著者	Tsukioki, Takahiro\| Shien, Tadahiko\| Tanaka, Takehiro\| Suzuki, Yoko\| Kajihara, Yukiko\| Hatono, Minami\| Kawada, Kengo\| Kochi, Mariko\| Iwamoto, Takayuki\| Ikeda, Hirokuni\| Taira, Naruto\| Doihara, Hiroyoshi\| Toyooka, Shinichi\|
キーワード	Breast cancer Metformin Preoperative Tils CD8 PD-L1
発行日	2020-06-12
出版物タイトル	Cancer Chemotherapy and Pharmacology
巻	86巻 86巻
号	1号 1号
出版者	Springer
開始ページ	55 55
終了ページ	63 63
ISSN	0344-5704
NCID	AA00598397
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
著作権者	©Author(s)
論文のバージョン	publisher
PubMed ID	32533334
DOI	10.1007/s00280-020-04092-2
Web of Science KeyUT	000539841500002
関連URL	isVersionOf https://doi.org/10.1007/s00280-020-04092-2

Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

フルテキストURL	fulltext.pdf
著者	Takahashi, Yuko\| Iwamoto, Takayuki\| Suzuki, Yoko\| Kajiwara, Yukiko\| Hatono, Minami\| Tsukioki, Takahiro\| Kawada, Kengo\| Kochi, Mariko\| Ikeda, Hirokuni\| Shien, Tadahiko\| Taira, Naruto\| Matsuoka, Junji\| Doihara, Hiroyoshi\| Toyooka, Shinichi\|
キーワード	Gene expression Hormone receptor positive Residual tumor burden Targeted therapy Triple negative
発行日	2020-04
出版物タイトル	Clinical Breast Cancer
巻	20巻
号	2号
出版者	Elsevier
開始ページ	117
終了ページ	124
ISSN	1526-8209
NCID	AA11694891
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
論文のバージョン	author
PubMed ID	31570267
DOI	10.1016/j.clbc.2019.07.001
Web of Science KeyUT	000529805200021
関連URL	isVersionOf https://doi.org/10.1016/j.clbc.2019.07.001

Evaluation of Prognosis of Juvenile Differentiated Thyroid Carcinoma

JaLCDOI	10.18926/AMO/60799
フルテキストURL	74_5_401.pdf
著者	Tsukioki, Takahiro\| Shien, Tadahiko\| Ohtani, Yusuke\| Fujihara, Miwa\| Suzuki, Yoko\| Kajihara, Yukiko\| Hatono, Minami\| Kawada, Kengo\| Kochi, Mariko\| Iwamoto, Takayuki\| Ikeda, Hirokuni\| Taira, Naruto\| Doihara, Hiroyoshi\|
抄録	Differentiated thyroid carcinoma (DTC) in juvenile patients is often an extensive and aggressive disease with a high frequency of recurrence. However, the prognosis is excellent, with a low mortality rate even when advanced disease is present, although prognostic factors and treatment strategy remain uncertain. Between April 2004 and March 2017, 33 juvenile patients (< 30 years old) were diagnosed with DTC and treated at our institution. We retrospectively investigated prognosis and factors including sex, reason for discovery, treatment, pathological factors and treatment progress to clarify the risk factors. All patients underwent curative surgical treatment. Pathologically, lymph node metastasis was identified in 25 patients (75%). Thirteen patients (39%) had bilateral cervical metastasis. In addition, 9 (27%) had more than 10 metastatic lymph nodes. The 2 patients with more than 20 metastatic lymph nodes were treated with radioactive iodine (RAI). Five patients (15%) had local recurrences and received surgery. There have been no further recurrences or deaths. However, no factors were determined to significantly predict the recurrence of juvenile DTC. Local recurrent disease was treated with surgery and/or RAI until remission, and survival was excellent in juvenile DTC.
キーワード	differentiated thyroid carcinoma juvenile children
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2020-10
巻	74巻
号	5号
出版者	Okayama University Medical School
開始ページ	401
終了ページ	406
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2020 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	33106695
Web of Science KeyUT	000581970100004
NAID	120006892925

Ectopic Breast Cancer Arising within an Axillary Lymph Node

JaLCDOI	10.18926/AMO/66676
フルテキストURL	78_1_089.pdf
著者	Toshima, Kei\| Shien, Tadahiko\| Nishimura, Midori Filiz\| Suzuki, Yoko\| Nakamoto, Shogo\| Uno, Maya\| Yoshioka, Ryo\| Tsukioki, Takahiro\| Takahashi, Yuko\| Iwamoto, Takayuki\| Iwatani, Tsuguo\| Yanai, Hiroyuki\|
抄録	We report our experience with the diagnosis and treatment of an ectopic breast cancer arising within an axillary lymph node. The patient was a 65-year-old woman diagnosed breast cancer and axillary lymph node metastasis. We performed a partial mastectomy and axillary lymph node dissection. Postoperative pathology revealed no malignant lesions in the breast; however, a nodule in one of axillary lymph nodes had mixed benign and malignant components, leading to a diagnosis of invasive ductal carcinoma derived from ectopic mammary tissue. This case represents a very rare form of breast cancer, and the malignancy was difficult to distinguish from metastasis.
キーワード	breast cancer ectopic breast cancer axillary lymph node
Amo Type	Case Report
出版物タイトル	Acta Medica Okayama
発行日	2024-02
巻	78巻
号	1号
出版者	Okayama University Medical School
開始ページ	89
終了ページ	93
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	Copyright Ⓒ 2024 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	38419320

Differences in Attitudes and Practices of Cancer Pain Management between Medical Oncologists and Palliative Care Physicians

JaLCDOI	10.18926/AMO/62394
フルテキストURL	75_4_431.pdf
著者	Kunitomi, Toshiki\| Nasu, Junichirou\| Minami, Daisuke\| Iwamoto, Takayuki\| Nishie, Hiroyuki\| Saito, Shinya\| Fujiwara, Toshiyoshi\| Matsuoka, Junji\|
抄録	This study aimed to evaluate whether there are differences in the attitudes and practices of cancer pain manage-ment between medical oncologists and palliative care physicians. An online nationwide survey was used to collect responses from board-certified medical oncologists and palliative care physicians in Japan. The survey questionnaire comprised 30 questions. The differences in responses between medical oncologists and palliative care physicians were examined. Out of the 1,227 questionnaires sent, 522 (42.5%) were returned. After apply-ing the exclusion criteria, 445 questionnaires (medical oncologists: n = 283; palliative care physicians: n = 162) were retained for analysis. Among the questions about potential barriers to optimal cancer pain man-agement, both medical oncologists and palliative care physicians considered the reluctance of patients to take opioids due to fear of adverse effects as the greatest barrier. Significantly different ratings between medical oncologists and palliative care physicians were observed on 5 of the 8 questions in this area. Significantly differ-ent ratings were observed for all questions concerning pain specialists and their knowledge. For effective cancer pain management, it is important to account for differences in attitudes and practice between medical oncolo-gists and palliative care physicians.
キーワード	cancer pain management opioid medical oncologist palliative care physician barriers
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2021-08
巻	75巻
号	4号
出版者	Okayama University Medical School
開始ページ	431
終了ページ	437
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2021 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	34511609
Web of Science KeyUT	000697944600004
NAID	120007146037

Development of a Japanese version of the BREAST-Q and the traditional psychometric test of the mastectomy module for the assessment of HRQOL and patient satisfaction following breast surgery

フルテキストURL	BreastCancer_24_4_593.pdf BreastCancer_24_4_593_tbl_fig.pdf
著者	Saiga, Miho\| Taira, Naruto\| Kimata, Yoshihiro\| Watanabe, Satoko\| Mukai, Yuko\| Shimozuma, Kojiro\| Mizoo, Taeko\| Nogami, Tomohiro\| Iwamoto, Takayuki\| Motoki, Takayuki\| Shien, Tadahiko\| Matsuoka, Junji\| Doihara, Hiroyoshi\|
キーワード	BREAST-Q Breast cancer Breast reconstruction Health-related quality of life Satisfaction
発行日	2017-03
出版物タイトル	Breast Cancer
巻	24巻
号	2号
出版者	Japanese Breast Cancer Society
開始ページ	288
終了ページ	298
ISSN	1340-6868
NCID	AA1103354X
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
著作権者	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
論文のバージョン	author
PubMed ID	27179527
DOI	10.1007/s12282-016-0703-6
Web of Science KeyUT	000395524900012
関連URL	isVerionOf https://doi.org/10.1007/s12282-016-0703-6

Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast

JaLCDOI	10.18926/AMO/53907
フルテキストURL	69_6_333.pdf
著者	Ito, Maiko\| Shien, Tadahiko\| Kaji, Mitsumasa\| Mizoo, Taeko\| Iwamoto, Takayuki\| Nogami, Tomohiro\| Motoki, Takayuki\| Taira, Naruto\| Doihara, Hiroyoshi\| Miyoshi, Shinichiro\|
抄録	We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients.
キーワード	breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2015-12
巻	69巻
号	6号
出版者	Okayama University Medical School
開始ページ	333
終了ページ	338
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	26690243
Web of Science KeyUT	000368434500002

Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer

フルテキストURL	fulltext.pdf
著者	Iwamoto, Takayuki\| Kajiwara, Yukiko\| Zhu, Yidan\| Iha, Shigemichi\|
キーワード	Biomarker chemotherapy breast cancer gene expression
発行日	2020-07
出版物タイトル	Chinese Clinical Oncology
巻	9巻
号	3号
出版者	AME
開始ページ	27
ISSN	2304-3865
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
論文のバージョン	publisher
PubMed ID	32192349
DOI	10.21037/cco.2020.01.06
Web of Science KeyUT	000543350700005
関連URL	isVersionOf 10.21037/cco.2020.01.06

A Phase I Trial of 100mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer

JaLCDOI	10.18926/AMO/54607
フルテキストURL	70_5_425.pdf
著者	Tamura, Tomoki\| Hirata, Taizo\| Tabata, Masahiro\| Hinotsu, Shiro\| Hamada, Akinobu\| Motoki, Takayuki\| Iwamoto, Takayuki\| Mizoo, Taeko\| Nogami, Tomohiro\| Shien, Tadahiko\| Taira, Naruto\| Matsuoka, Junji\| Doihara, Hiroyoshi\|
抄録	Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
キーワード	breast cancer phase I trial docetaxel
Amo Type	Clinical Study Protocols
出版物タイトル	Acta Medica Okayama
発行日	2016-10
巻	70巻
号	5号
出版者	Okayama University Medical School
開始ページ	425
終了ページ	427
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	27777441
Web of Science KeyUT	000388098700018

岩本 高行